Toxicity, Dose Intensity, and Clinical Outcomes with First-Line Enfortumab Vedotin Plus Pembrolizumab in Advanced Urothelial Carcinoma: A Multicenter Real-World Study

Samad Sayed, Rishikesh Kumar, Martin Zarba, Md Mahsin, Amina Taleb, Lateefah Alshammari, Simon Mairs, Naveen Basappa, Michael Kolinsky, Meghan Mahoney, Vishal Navani, Tina Cheng, Safiya Karim, Richard Lee-Ying, Steven Yip, Daniel Y. C. Heng, Scott North, Nimira Alimohamed

Open source

DOI: 10.3390/curroncol33090542
Published: 2026-09-09
Container: Current Oncology
Publisher: MDPI AG
Open access: unknown

Credibility signals

uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

supportingDOI registered: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
supportingDOI resolves: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
supportingMetadata completeness: All 6 scored descriptive metadata groups are present. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.3390/curroncol33090542,
  title = {Toxicity, Dose Intensity, and Clinical Outcomes with First-Line Enfortumab Vedotin Plus Pembrolizumab in Advanced Urothelial Carcinoma: A Multicenter Real-World Study},
  author = {Samad Sayed and Rishikesh Kumar and Martin Zarba and Md Mahsin and Amina Taleb and Lateefah Alshammari and Simon Mairs and Naveen Basappa and Michael Kolinsky and Meghan Mahoney and Vishal Navani and Tina Cheng and Safiya Karim and Richard Lee-Ying and Steven Yip and Daniel Y. C. Heng and Scott North and Nimira Alimohamed},
  year = {2026},
  journal = {Current Oncology},
  doi = {10.3390/curroncol33090542},
  url = {https://doi.org/10.3390/curroncol33090542}
}

RIS

TY  - JOUR
TI  - Toxicity, Dose Intensity, and Clinical Outcomes with First-Line Enfortumab Vedotin Plus Pembrolizumab in Advanced Urothelial Carcinoma: A Multicenter Real-World Study
AU  - Samad Sayed
AU  - Rishikesh Kumar
AU  - Martin Zarba
AU  - Md Mahsin
AU  - Amina Taleb
AU  - Lateefah Alshammari
AU  - Simon Mairs
AU  - Naveen Basappa
AU  - Michael Kolinsky
AU  - Meghan Mahoney
AU  - Vishal Navani
AU  - Tina Cheng
AU  - Safiya Karim
AU  - Richard Lee-Ying
AU  - Steven Yip
AU  - Daniel Y. C. Heng
AU  - Scott North
AU  - Nimira Alimohamed
PY  - 2026
JO  - Current Oncology
DO  - 10.3390/curroncol33090542
UR  - https://doi.org/10.3390/curroncol33090542
ER  -

APA

Sayed, S., Kumar, R., Zarba, M., Mahsin, M., Taleb, A., Alshammari, L., Mairs, S., Basappa, N., Kolinsky, M., Mahoney, M., Navani, V., Cheng, T., Karim, S., Lee-Ying, R., Yip, S., Heng, D. Y. C., North, S., & Alimohamed, N. (2026). Toxicity, Dose Intensity, and Clinical Outcomes with First-Line Enfortumab Vedotin Plus Pembrolizumab in Advanced Urothelial Carcinoma: A Multicenter Real-World Study. Current Oncology. https://doi.org/10.3390/curroncol33090542

Source records

crossref · retrieved 2026-09-25T12:12:33.773Z